These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 16952623)

  • 21. Age of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK.
    Evans CE; Mylchreest S; Andrew JG
    BMC Musculoskelet Disord; 2006 Mar; 7():21. PubMed ID: 16519799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in receptor activator of nuclear factor-kappaB, and its ligand, osteoprotegerin, bone-type alkaline phosphatase, and tartrate-resistant acid phosphatase in ovariectomized rats.
    Miyazaki T; Matsunaga T; Miyazaki S; Hokari S; Komoda T
    J Cell Biochem; 2004 Oct; 93(3):503-12. PubMed ID: 15372622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.
    Korpela J; Tiitinen SL; Hiekkanen H; Halleen JM; Selander KS; Väänänen HK; Suominen P; Helenius H; Salminen E
    Anticancer Res; 2006; 26(4B):3127-32. PubMed ID: 16886645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Osteoprotegerin and RANKL in alcoholic liver cirrhosis.
    Fábrega E; Orive A; García-Suarez C; García-Unzueta M; Antonio Amado J; Pons-Romero F
    Liver Int; 2005 Apr; 25(2):305-10. PubMed ID: 15780054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
    Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
    Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum markers of bone turnover in dialyzed patients grouped by level of intact parathyroid hormone.
    Grzegorzewska AE; Mlot-Michalska M
    Adv Perit Dial; 2006; 22():203-6. PubMed ID: 16983970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75].
    Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang LZ; Xu MY; Chen JL
    Zhonghua Nei Ke Za Zhi; 2004 Jun; 43(6):447-50. PubMed ID: 15312444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand.
    Lee CK; Lee EY; Chung SM; Mun SH; Yoo B; Moon HB
    Arthritis Rheum; 2004 Dec; 50(12):3831-43. PubMed ID: 15593184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum levels of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand as markers of periprosthetic osteolysis.
    Granchi D; Pellacani A; Spina M; Cenni E; Savarino LM; Baldini N; Giunti A
    J Bone Joint Surg Am; 2006 Jul; 88(7):1501-9. PubMed ID: 16818976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. News on biomarkers in CKD-MBD.
    Mazzaferro S; Tartaglione L; Rotondi S; Bover J; Goldsmith D; Pasquali M
    Semin Nephrol; 2014 Nov; 34(6):598-611. PubMed ID: 25498379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover.
    Indridason OS; Franzson L; Sigurdsson G
    Osteoporos Int; 2005 Apr; 16(4):417-23. PubMed ID: 15776220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.
    Terpos E; Szydlo R; Apperley JF; Hatjiharissi E; Politou M; Meletis J; Viniou N; Yataganas X; Goldman JM; Rahemtulla A
    Blood; 2003 Aug; 102(3):1064-9. PubMed ID: 12689925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis.
    Park HR; Min SK; Cho HD; Kim DH; Shin HS; Park YE
    J Korean Med Sci; 2003 Aug; 18(4):541-6. PubMed ID: 12923331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Relationship between coronary and abdominal calcification score, serum osteoprotegerin (OPG), and serum tartrate-resistant acid phosphatase (TRACP) -5b in pre-dialysis CKD patients].
    Shiota J; Izumi N; Kasahara H; Tagawa H; Chiba T; Nihei H
    Nihon Jinzo Gakkai Shi; 2010; 52(8):1022-8. PubMed ID: 21254698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG).
    Sasaki N; Kusano E; Takahashi H; Ando Y; Yano K; Tsuda E; Asano Y
    J Bone Miner Metab; 2005; 23(1):41-7. PubMed ID: 15616893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
    Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
    Terpos E; Heath DJ; Rahemtulla A; Zervas K; Chantry A; Anagnostopoulos A; Pouli A; Katodritou E; Verrou E; Vervessou EC; Dimopoulos MA; Croucher PI
    Br J Haematol; 2006 Dec; 135(5):688-92. PubMed ID: 17107351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment.
    Rogers A; Eastell R
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6323-31. PubMed ID: 16105967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury?
    Masi L; Simonini G; Piscitelli E; Del Monte F; Giani T; Cimaz R; Vierucci S; Brandi ML; Falcini F
    J Rheumatol; 2004 May; 31(5):986-91. PubMed ID: 15124262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.
    Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Tziamalis MP; Tsigris C; Kostaki MA; Perrea DN
    J Endocrinol Invest; 2007 Oct; 30(9):762-6. PubMed ID: 17993768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.